Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia

被引:37
作者
Farnier, M [1 ]
Dejager, S
机构
[1] Rond Point Nation, Point Med, F-21000 Dijon, France
[2] Novartis Pharma SA, Rueil Malmaison, France
关键词
D O I
10.1016/S0002-9149(99)00606-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This double-blind study was designed to assess the efficacy and safety of fluvastatin-fenofibrate combination therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol greater than or equal to 190 mg/dl [4.9 mmol/L], triglycerides less than or equal to 350mg/dl [3.9 mmol/l]). After a 10-week placebo and dietary baseline period, 102 patients were randomized to receive micronized fenofibrate 200 mg, fluvastatin 20 mg plus micronized fenofibrate 200 mg, or fluvastatin 40 mg plus micronized fenofibrate 200 mg. At week 16, fenofibrate 200 mg alone lowered LDL cholesterol from baseline by 21% compared with 32% for fluvastatin 20 mg plus fenofibrate 200 mg and 41% for fluvastatin 40 mg plus fenofibrate 200 mg (p < 0.001). Triglycerides decreased by 29% with fenofibrate 200 mg alone, 39% with fluvastatin 20 mg plus fenofibrate 200 mg, and 40% with fluvastatin 40 mg plus fenofibrate 200 mg (p < 0.05). Safety was assessed by recording adverse events and measuring clinical laboratory parameters. The adverse event profile wets similar for the 3 treatment groups. One patient withdrew due to an increase in transaminase levels. No significant increase in creatine phosphokinase levels was observed with combination therapy. In conclusion, the addition of fluvastatin to micronized fenofibrate results in substantial improvement in atherogenic plasma lipids and is well tolerated. (C) 2000 by Excerpta Medica, Inc.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 22 条
[11]  
FEHER MD, 1995, BRIT HEART J, V74, P14
[12]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[13]  
Fruchart JC, 1998, AM J CARDIOL, V81, P912
[14]   Fluvastatin - A review of its use in lipid disorders [J].
Langtry, HD ;
Markham, A .
DRUGS, 1999, 57 (04) :583-606
[15]   EFFICACY AND SAFETY OF A COMBINATION FLUVASTATIN-BEZAFIBRATE TREATMENT FOR FAMILIAL HYPERCHOLESTEROLEMIA - COMPARATIVE-ANALYSIS WITH A FLUVASTATIN-CHOLESTYRAMINE COMBINATION [J].
LEITERSDORF, E ;
MURATTI, EN ;
ELIAV, O ;
MEINER, V ;
EISENBERG, S ;
DANN, EJ ;
SEHAYEK, E ;
PETERS, TK ;
STEIN, Y .
AMERICAN JOURNAL OF MEDICINE, 1994, 96 (05) :401-407
[16]   RHABDOMYOLYSIS AND ACUTE-RENAL-FAILURE INDUCED BY COMBINATION LOVASTATIN AND GEMFIBROZIL THERAPY [J].
MARAIS, GE ;
LARSON, KK .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (03) :228-230
[17]   MYOPATHY AND RHABDOMYOLYSIS ASSOCIATED WITH LOVASTATIN-GEMFIBROZIL COMBINATION THERAPY [J].
PIERCE, LR ;
WYSOWSKI, DK ;
GROSS, TP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (01) :71-75
[18]   Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy [J].
Pogson, GW ;
Kindred, LH ;
Carper, BG .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (07) :1146-+
[19]   FIBRATES AND STATINS IN THE TREATMENT OF HYPERLIPIDEMIA - AN APPRAISAL OF THEIR EFFICACY AND SAFETY [J].
SHEPHERD, J .
EUROPEAN HEART JOURNAL, 1995, 16 (01) :5-13
[20]  
SMIT WAJ, 1995, AM J CARDIOL, V76, pA126